American Cancer Immunotherapy Market Compressive Study with Healthy CAGR of 10.1%
Added: (Wed Dec 05 2018)
Pressbox (Press Release) -
Market Report Titled "Cancer Immunotherapy Market Research Report – Forecast to 2023" is a Specialist Examination Report Explores the Industry by Research Methodology, Segmentation, Key Players, and Major Region Globally .
Cancer Immunotherapy Market - Overview
Cancer Immunotherapy is an advanced paradigm in cancer therapeutics. Cancer immunotherapy works by enhancing the patient’s immune system. This is generally accompanied by the administration of synthesized immune proteins.
The most common therapeutic areas of cancer immunotherapy are inclusive of breast, prostate, lung cancer, and others. Increasing prevalence of the cancer is one of the major drivers for the market growth during the forecast period.
GET FREE SAMPLE REPORT @ https://www.marketresearchfuture.com/sample_request/592
According to the National Cancer Institute in 2016, an estimated 1,685,210 new cases of cancer were diagnosed in the U.S. and approximately 595,690 people died due to cancer within the region.
Moreover, it was estimated that the national healthcare expenditures for cancer care in the U.S. totalled nearly to USD 125 billion in 2010, and it is expected to reach USD 156 billion by 2020.
Cancer Immunotherapy Market - Key Players
Amgen Inc. (U.S.)
F. Hoffmann-La Roche Ltd. (Switzerland)
Bayer AG (Germany)
Bristol-Myers Squibb Company (U.S.)
Eli Lilly and Company (U.S.)
Merck & Co., Inc. (U.S.)
Pfizer Inc. (U.S.)
Novartis AG (Switzerland)
Cancer Immunotherapy Market - Segmentation
The Americas cancer immunotherapy market is segmented on the basis of cancer, therapeutics, and end users. On the basis of the cancer, the market is segmented into lung cancer, prostate cancer, colorectal cancer, head & neck cancer, and others.
On the basis of the therapeutics, the market is segmented into monoclonal antibodies, immune checkpoint inhibitors, vaccines, non-specific cancer immunotherapies and adjuvants, and others.
The naked monoclonal antibodies segment, by monoclonal antibody segment, is father segmented into alemtuzumab, trastuzumab, and others.
OBTAIN COMPLETE 90 PAGES PREMIUM RESEARCH REPORT DETAILS ENABLED WITH RESPECTIVE 40+ TABLES AND FIGURES @ https://www.marketresearchfuture.com/reports/cancer-immunotherapy-market-592
Cancer Immunotherapy Market - Regional Analysis
On regional basis the Americas is divided into North America and Latin America. North America is sub segmented into U.S. and Canada. North America commands for the largest market share for the Americas cancer immunotherapy market due the presence of the U.S. within the region.
This large share is also attributed due to the technologically advanced healthcare market in the region which is followed by high prevalence of cancer, increasing development in cancer immunotherapy treatment and rising per capita healthcare expenditure.
The total number of the biotechnology industries in the U.S. increased from 2,763 in 2014 and reached 2,772 in 2015. Additionally, the abundance of state of the art laboratories in the U.S. is also facilitating the market growth.
Major Points form Table of Content
Chapter 1. Report Prologue
Chapter 2. Market Introduction
Chapter 3. Research Methodology
Chapter 4. Market Dynamics
Chapter 5. Market Factor Analysis
Chapter 6. Cancer Immunotherapy Market, By Type
Chapter 7. Cancer Immunotherapy Market, By Treatment
Chapter 8 Cancer Immunotherapy Market, By End User
Chapter 9. Cancer Immunotherapy Market, By Region
Chapter 10 Company Landscape
Chapter 11 Company Profiles
Chapter 12 MRFR Conclusion
Chapter 13 Appendix
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Phone: +1 646 845 9312